Skip to main content

PT Pyridam Farma Tbk (PYFA.JK)

Indonesia Stock Exchange Healthcare Drug Manufacturers - Specialty & GenericView data quality →
32.0Poor

ValueMarkers Composite Index

Top 0%#44,525 of 44,714

DCF data not available

Piotroski
4/9
Neutral
Beneish
-2.37
Low Risk
Altman
0.68
Distress
DCF Value
-
N/A
ROIC
-2.0%
Low
P/E
-
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

PT Pyridam Farma Tbk (PYFA.JK) — VMCI valuation read

Across 120 indicators, PT Pyridam Farma Tbk (PYFA.JK) lands at VMCI 32/100. The Healthcare sector median is 50, so the 18-point below-median read is the active comparison. Pillar weighting on the score: Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%.

No material Form 4 disclosures landed on PYFA.JK in the past 30 days. Quiet insider tape removes one signal source; the active reads stay with the trailing-twelve-month financials and the next 10-Q.

**Investor frame.** On Value, PYFA.JK trades at 17.0x earnings, 6% below the Healthcare median of 18.0x; the EV/EBITDA delta of -2.0x reinforces that single line. On Quality, ROIC of 13.0% sits 3.0pp above the Healthcare median (10.0%). On Risk, net debt to EBITDA of 1.4x leaves covenant headroom for PYFA.JK on the trailing balance sheet.

PYFA.JK fell 0.7% over the trailing 7 days, with a +6.6% read on a 30-day basis.

PT Pyridam Farma Tbk develops, produces, and sells pharmaceuticals, antibiotics, vitamins, supplements, and traditional herbal care products in Indonesia. The company operates in two segments, Pharmaceutical Products and Toll Manufacturing Services; and Medical Device Products. It offers medical instruments and equipment, including clinical waste, collection swab, collection tube, innerbox DCA, KF94 mask, parafilm, PCR – extraction kit and extractor machine, speciment bag, sterile container, and tube stopper. The company also provides skin care products comprising Arosa gel, A-Stark Gel, Hymen gel, Pyderen Emulsion, Tonic Bust Emulsion, Calmosan Cream, and Di-Herb gel; products in the areas of alimentary t. and metabolism, blood and blood forming organs, cardiovascular system, dermatologicals, G.U. system and sex hormones, systemic corticosteroids, systemic antibacterial, sensory organs, as well as musculo-skeletal, nervous, and respiratory systems; and supplements and other preventive consumer health products with energy drinks and healthy ready-to-drink products. In addition, it engages in the research and development on biotechnology, life, and medical science. The company was founded in 1976 and is headquartered in Jakarta, Indonesia.

CEO: Yan Gwan Lee1,943 employeesIDwww.pyfa.co.id

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in PYFA.JK’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.